Scholarlink

Background <p>Alogliptin (ALO) selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and Canagliflozin is the sodium-glucose cotransporter-2 (SGLT-2) inhibitor against type 2 diabetes mellitus.</p> Purpose <p>The study aimed to spectrophotometric simultaneous novel method development and validation of antidiabetic drugs Alogliptin (ALO) and Canagliflozin (CANA).</p> Results <p>A linear response was observed over a concentration range of 10–100&#xa0;µg/mL for both compounds, achieving high correlation coefficients (R²) of 0.999, indicating excellent analytical reliability. The limits of detection (LOD) for CANA and ALO were determined to be 1.65&#xa0;µg/mL and 8.8&#xa0;µg/mL while the limits of quantification (LOQ) for CANA and ALO were 5.0&#xa0;µg/mL and 26&#xa0;µg/mL, respectively. The method was rigorously validated as per International Conference on Harmonization (ICH) Q2R1guidelines, assessing key parameters such as linearity, precision, accuracy, sensitivity, and robustness. Intra-day and inter-day precision studies yielded relative standard deviation (RSD) values below 2%, confirming the method’s reproducibility. Recovery studies demonstrated high accuracy, with recovery values for CANA and ALO ranging from 98 to 102%, further validating the method’s effectiveness. The study also evaluated the ruggedness of the method, with results showing acceptable limits and a % RSD value of less than 2% across different analysts and trials.</p> Conclusion <p>The UV spectrophotometric method developed is simple, cost-effective, and timesaving, making it suitable for routine estimation of ALO and CANA in both bulk and dosage forms. This method can be effectively applied for quality control, pharmacokinetic, and stability studies, thereby contributing significantly to the field of pharmaceutical analysis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Spectrophotometric Methods for Simultaneous Development and Validation of Anti-diabetic drug Alogliptin and Canagliflozin

  • 期刊论文

  • 发表日期：

    2025年7月30日

查看全文
  • Aniket Bhardwaj,
  • Saurabh Verma,
  • Vikesh Kumar Shukla,
  • Havagiray R. Chitme

摘要

Background

Alogliptin (ALO) selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and Canagliflozin is the sodium-glucose cotransporter-2 (SGLT-2) inhibitor against type 2 diabetes mellitus.

Purpose

The study aimed to spectrophotometric simultaneous novel method development and validation of antidiabetic drugs Alogliptin (ALO) and Canagliflozin (CANA).

Results

A linear response was observed over a concentration range of 10–100 µg/mL for both compounds, achieving high correlation coefficients (R²) of 0.999, indicating excellent analytical reliability. The limits of detection (LOD) for CANA and ALO were determined to be 1.65 µg/mL and 8.8 µg/mL while the limits of quantification (LOQ) for CANA and ALO were 5.0 µg/mL and 26 µg/mL, respectively. The method was rigorously validated as per International Conference on Harmonization (ICH) Q2R1guidelines, assessing key parameters such as linearity, precision, accuracy, sensitivity, and robustness. Intra-day and inter-day precision studies yielded relative standard deviation (RSD) values below 2%, confirming the method’s reproducibility. Recovery studies demonstrated high accuracy, with recovery values for CANA and ALO ranging from 98 to 102%, further validating the method’s effectiveness. The study also evaluated the ruggedness of the method, with results showing acceptable limits and a % RSD value of less than 2% across different analysts and trials.

Conclusion

The UV spectrophotometric method developed is simple, cost-effective, and timesaving, making it suitable for routine estimation of ALO and CANA in both bulk and dosage forms. This method can be effectively applied for quality control, pharmacokinetic, and stability studies, thereby contributing significantly to the field of pharmaceutical analysis.